Ludmila Prudkin

Isdin (Spain) — Spain

Medicine · Health Sciences

30h-index6.2kcitations163works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(68), Lung Cancer Treatments and Mutations(48), PI3K/AKT/mTOR signaling in cancer(32), Monoclonal and Polyclonal Antibodies Research(32), Cancer, Hypoxia, and Metabolism(14)

Publications163 total

An Assessment of the Antifungal Efficacy of a Novel Topical Onychomycosis Treatment Using Human Nail and Skin Infection Models
Journal of Fungi·2025Open Access
[Artículo traducido] La contaminación, un factor relevante del exposoma en el envejecimiento cutáneo y el papel de la fotoprotección multibeneficio
Actas Dermo-Sifiliográficas·2025Open Access
Pollution, a Relevant Exposome Factor in Skin Aging and the Role of Multi-benefit Photoprotection
Actas Dermo-Sifiliográficas·2025· 3 citedOpen Access
The exposome impact on hair health: non-pharmacological management. Part II⋆
Anais Brasileiros de Dermatologia·2025· 1 citedOpen Access
The exposome impact on hair health: etiology, pathogenesis and clinical features ‒ Part I
Anais Brasileiros de Dermatologia·2024· 4 citedOpen Access
Sunscreens prescribed to patients with skin of color and/or with melasma: A survey of 221 dermatologists and dermatology residents in Spain
Photodermatology Photoimmunology & Photomedicine·2024· 5 cited
Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology
Clinical Cosmetic and Investigational Dermatology·2024· 1 citedOpen Access
Exposome Impact on Nail Health
Skin Appendage Disorders·2024· 1 citedOpen Access
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Table 1 from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i><sup>V659E</sup> Mutation
2023Open Access
Data from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i><sup>V659E</sup> Mutation
2023Open Access
Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 2 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Data from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends 1-3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i><sup>V659E</sup> Mutation
2023Open Access
Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i><sup>V659E</sup> Mutation
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Ignacio I. Wistuba(14), Maurizio Scaltriti(13), José Baselga(13), Violeta Serra(11), José Jiménez(11), Paolo Nucíforo(11), José Baselga(9), Claudia Aura(9), Josep Tabernero(9), Carmen Behrens(7), Jordi Rodón(6), Joaquı́n Arribas(6), Olga Rodríguez(5), Marta Guzmán(5), Catherine Ellis(5), Yasir H. Ibrahim(4), Javier Cortés(4), Jack A. Roth(4), Holger Eidtmann(4), Martine Piccart(4)